VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ISA 2022 | Feasibility of BCMA-directed CAR-T therapy in R/R AL amyloidosis

Moshe Gatt, MD, Hadassah Medical Center, Jerusalem, Israel, discusses the results of a Phase I study evaluating the feasibility of HBI0101 (NCT04720313), a novel academic BCMA-directed CAR-T therapy for the treatment of relapsed/refractory (R/R) amyloidosis. In addition to a high rate of complete remission and MRD negativity, patients had impressive organ responses, with a significant reduction in cardiac proBNP and disappearance of proteinuria. Nevertheless, some patients experienced cytokine release syndrome (CRS) and congestive heart failure, and it is still necessary to determine the durability of these CAR-Ts. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter